STOCK TITAN
  1. Home
  2. News
  3. ADXS

Ayala Pharmaceuticals Inc. - ADXS STOCK NEWS

Welcome to our dedicated news page for Ayala Pharmaceuticals (Ticker: ADXS), a resource for investors and traders seeking the latest updates and insights on Ayala Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ayala Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ayala Pharmaceuticals's position in the market.

News
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
Rhea-AI Summary
Ayala Pharmaceuticals, Inc. completes the sale of AL102 and AL101 to Immunome, Inc. for $20 million in cash, 2,175,489 shares of Immunome common stock, and potential milestone payments of up to $37.5 million. The sale includes the transfer of specified liabilities related to AL102. Ayala expresses satisfaction with the transaction, highlighting the expertise of Immunome in advancing AL102.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.7%
Tags
none
-
News
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Rhea-AI Summary
Ayala Pharmaceuticals Completes Patient Enrollment in Phase 3 RINGSIDE Study for AL102 in Desmoid Tumors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
clinical trial
-
News
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
Rhea-AI Summary
Immunome, Inc. has entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. to acquire AL102 and related drug candidate AL101. The agreement includes a $20 million cash payment and $30 million in Immunome common stock, with up to an additional $37.5 million in milestone payments. AL102 is a small molecule gamma secretase inhibitor currently being evaluated in a Phase 3 trial for the treatment of desmoid tumors, showing promising results in terms of tumor reduction and anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
122.07%
Tags
acquisition clinical trial
News
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
Rhea-AI Summary
Ayala Pharmaceuticals receives FDA Orphan Drug Designation for AL102, a Gamma Secretase Inhibitor (GSI), for the treatment of desmoid tumors (DT). Desmoid tumors are rare connective tissue tumors that affect approximately 1,700 patients in the US annually. AL102 is currently being evaluated in the Phase 3 RINGSIDE study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
clinical trial
-
News
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
Rhea-AI Summary
Ayala Pharmaceuticals announces positive results from the RINGSIDE study evaluating AL102 for the treatment of desmoid tumors. The treatment achieved an Overall Response Rate of 83% in the evaluable population, with an 88% reduction in tumor volume and 85% reduction in T2W signal intensity. Phase 3 registration segment of RINGSIDE is enrolling patients globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
Rhea-AI Summary
Ayala Pharmaceuticals completes merger with Biosight, expands product pipeline
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
acquisition
News
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Ayala Pharmaceuticals announces successful End-of-Phase 2 meeting with FDA regarding AL102 for desmoid tumors. Enrollment in Phase 3 of RINGSIDE trial continuing as planned. Definitive merger agreement with Biosight expected to close in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
earnings
-
News
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
Rhea-AI Summary
Ayala Pharmaceuticals, Inc. will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Society for Molecular Oncology (ESMO) Congress 2023. The Phase 2 results of AL102 for the treatment of Desmoid Tumors and the final results of the ACCURACY trial for AL101 therapy in patients with recurrent/metastatic adenoid cystic carcinoma (ACC) will be presented.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.59%
Tags
none
-
News
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Rhea-AI Summary
Ayala Pharmaceuticals, Inc. and Biosight Ltd. have entered into a definitive merger agreement. The combined company will operate as Ayala Pharmaceuticals, Inc. and will focus on advancing a portfolio of oncology assets. Ayala's AL102 and Biosight's Aspacytarabine will be the primary focus. AL102 has shown promising results in the treatment of desmoid tumors, with a 50% partial response rate and 100% disease control rate in Phase 2. The merger aims to create sustainable value for patients and shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.91%
Tags
acquisition
News
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.94%
Tags
clinical trial
Stock ADXS logo
Ayala Pharmaceuticals Inc.

OTC:ADXS

ADXS Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ADXS Stock Data

25.62M
0.02%
16.65%
0.54%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Princeton

About ADXS

advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.